- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02019524
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)
Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
Study Overview
Status
Conditions
Detailed Description
The study is a prospective, randomized, non-blinded, single-center Phase Ib trial. Patients will be identified that have a diagnosis of breast or ovarian cancer, have completed their standard courses of therapy and are disease-free. They will be properly screened, counseled and consented prior to enrollment. Once enrolled, each patient's blood will be tested for HLA-A2 status (approximately 50% will be HLA-A2+). Additionally, their tumors will be tested for FBP-expression and this information will be tracked for purposes of correlative science.
Patients who are HLA-A2+ will be stratified based on cancer diagnosis (breast versus ovarian), then randomized by computer tables to one of three arms for the PVS. Each arm will receive 6 monthly injections of peptide + GM-CSF. Arm A will receive six inoculations with E39 peptide; arm B will receive three inoculations with E39 followed by three with J65; and arm C will receive three inoculations with J65, followed by three of E39. Since J65 has not been previously used in humans, a two week waiting period will be instituted between the first and second patients enrolled in either Arm B or C. Immunologic data will be assessed at 1 month and 6 months (±2 wks) after the PVS, specifically ex vivo immunologic recognition of E39 and J65 will be assessed by clonal expansion using a dextramer assay and the in vivo response will be assessed by Delayed Type Hypersensitivity (DTH). Immunologic recognition of E39 will be the primary endpoint, with recognition of J65 serving as an additional data point. The 6 month post-PVS immunologic data will then be used to assess each patient for significant residual immunity (SRI), defined as ≥2-fold increase in E39-specific CD8+ T-cells from the pre-vaccination level. Patients will then be sorted into two groups: those with SRI and those without. Patients within each group will then be randomized to receive one booster of either J65 or E39. Each patient will return to clinic within 1-2 weeks of their 6mo post-PVS visit to receive their single booster inoculation. This second randomization will result in four groups: 1) patients with SRI receiving E39; 2) patients with SRI receiving J65; 3) patients without SRI receiving E39; 4) patients without SRI receiving J65. Immunologic data will then again be gathered at 1 month (±2 wks) and 6 months (±2 wks) post-booster. This final immunologic data will be analyzed for differences between the four groups. Additionally, toxicity data will be gathered.
Patients will be monitored closely for one hour after each inoculation with questioning, serial exams, and vital signs every 15 minutes. Patients will then be asked to return to the vaccine clinic 48-72 hours after each inoculation for questioning regarding any local or systemic toxicity and to examine and measure the local reaction at the vaccination sites. The graded toxicity scale (NCI Common Terminology Criteria for Adverse Events, v4.03) will be utilized to assess local and systemic toxicity. GM-CSF dose reduction may be required if >10cm of erythema and induration is seen at the injection site after any given inoculation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas M.D. Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have breast or ovarian cancer
- Patients must have completed primary breast or ovarian cancer therapy (i.e., surgery, chemotherapy, immunotherapy and/or radiation therapy as appropriate per standard of care for patient's specific cancer)
- Patients must be without evidence of residual disease as assessed by their treatment team
- Patients must be either post-menopausal or surgically post-menopausal
- Patients must be HLA-A2 positive
- Patients must have a good performance status (ECOG<2)
Exclusion Criteria:
- HLA-A2 negative patients
- Currently receiving immunosuppressive therapy to include chemotherapy, steroids, or methotrexate
- In poor health (Karnofsky <60%, ECOG >2)
- Total bilirubin >1.5, creatinine >2, hemoglobin <10, platelets <50,000, WBC <2,000
- Active pulmonary disease requiring medication to include multiple inhalers
- Of child-bearing age with intact reproductive organs
- Involved in other experimental protocols (except with permission of the other study PI)
- History of autoimmune disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E39 peptide vaccine
Patients receive 6 monthly injections of E39 peptide + GM-CSF.
Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity.
The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity.
Patients are then sorted into two groups: those with SRI and those without.
Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine.
Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
|
500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen.
At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe.
This constitutes the E39 peptide vaccine.
For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations.
After completion of the PVS, patients are assessed for significant residual immunity (SRI).
Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
Other Names:
|
Experimental: E39 vaccine then J65 vaccine
Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine.
Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity.
The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity.
Patients are then sorted into two groups: those with SRI and those without.
Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine.
Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
|
The E39 vaccine is prepared as noted above.
For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen.
At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe.
This constitutes the J65 vaccine.
For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations.
Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations.
After completion of the PVS, patients are assessed for significant residual immunity (SRI).
Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Other Names:
|
Experimental: J65 vaccine then E39 vaccine
Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine.
Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity.
The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity.
Patients are then sorted into two groups: those with SRI and those without.
Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine.
Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
|
The E39 and J65 vaccines are prepared as noted above.
For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations.
Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations.
After completion of the PVS, patients are assessed for significant residual immunity (SRI).
Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary vaccination strategy
Time Frame: Six months after completion of primary vaccination series (month 12 of trial)
|
Determine which of the following primary vaccination strategy maximizes long-term specific immunity defined as E39-specific cytotoxic T lymphocytes (CTLs) six months following completion of the primary vaccination series.
|
Six months after completion of primary vaccination series (month 12 of trial)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short-term immunity
Time Frame: One month after completion of primary vaccination series (month 7 of trial)
|
To determine the most effective vaccination strategy to maximize short-term immunity defined as E39-specific CTLs one month following completion of the primary vaccination series.
|
One month after completion of primary vaccination series (month 7 of trial)
|
Optimal booster inoculation strategy
Time Frame: Twelve months after completion of primary vaccination series (month 18 of trial)
|
To determine the most effective booster inoculations (i.e., E39 or J65 peptides) to maximize long-lasting immunity defined as E39-specific cytotoxic T lymphocytes six months following administration of the booster inoculations.
|
Twelve months after completion of primary vaccination series (month 18 of trial)
|
Delayed Type Hypersensitivity evaluation
Time Frame: Baseline to six months after completion of primary vaccination series (month 18 of trial)
|
Mean change in size of Delayed Type Hypersensitivity (DTH) reactions from baseline to 12 months post-completion of the primary vaccination series.
Measurements of DTH reactions will be taken at baseline, then at month 7, 12, 17 and 18.
|
Baseline to six months after completion of primary vaccination series (month 18 of trial)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Elizabeth Mittendorf, MD, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Breast Diseases
- Genetic Diseases, Inborn
- Neoplastic Syndromes, Hereditary
- Breast Neoplasms
- Ovarian Neoplasms
- Carcinoma, Ovarian Epithelial
- Hereditary Breast and Ovarian Cancer Syndrome
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Micronutrients
- Vitamins
- Hematinics
- Vaccines
- Folic Acid
- Vitamin B Complex
- Sargramostim
- Molgramostim
Other Study ID Numbers
- 2013-0139
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on E39 peptide vaccine
-
COL George Peoples, MD, FACSCompletedOvarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian CancerUnited States
-
National Liver Institute, EgyptUnknownVaccine Overdose of Undetermined IntentEgypt
-
National Cancer Institute (NCI)CompletedStage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin MelanomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...RecruitingNSCLC Stage IV | ALK Fusion Protein ExpressionUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian CancerUnited States
-
University Hospital TuebingenCooperative Weichteilsarkom Study Group; Deutsches Konsortium fürTranslationale... and other collaboratorsRecruitingEwing Sarcoma | Rhabdomyosarcoma | Synovial SarcomaGermany
-
Sellas Life Sciences GroupCompletedAcute Myeloid Leukemia | Acute Lymphoblastic LeukemiaUnited States
-
zeinab ahmed yousif hasan ashourRecruiting
-
Herbert LyerlyRecruiting
-
Hadassah Medical OrganizationVaxil Therapeutics Ltd.WithdrawnMultiple Myeloma | TumorsIsrael